Find in Library

<p>Abstract</p> <p>Background</p> <p>The C-terminal region of merozoite surface protein-1 (MSP-1) is one of the leading candidates for vaccination against the erythrocytic stages of malaria. However, a major concern in the development of MSP-1 based malaria vaccine is the polymorphism observed in different geographical <it>Plasmodium falciparum </it>isolates. To explore whether the sequence heterogeneity of PfMSP-1 leads to variation in naturally acquired anti-MSP-1₁₉antibodies, the present study was undertaken to study PfMSP-1₁₉sequence polymorphism in malaria-endemic villages in eastern India and also carried out a competition enzyme-linked immunosorbent assay using three PfMSP-1₁₉variant forms.</p> <p>Methods</p> <p>The sequence variations in the C-terminal region of PfMSP-1₁₉were determined in a malaria endemic region. Three PfMSP-1₁₉variants were produced in <it>Escherichia coli </it>(PfMSP1₁₉QKNG-L, PfMSP1₁₉EKNG-L and PfMSP1₁₉ETSR-F) and an immunodepletion assay was carried out using the corresponding patients' sera.</p> <p>Results</p> <p>Results revealed predominance of PfMAD20 allele among Indian field isolates. Seven PfMSP-1₁₉variant forms were isolated in a singe geographical location. Three of PfMSP-1₁₉variant forms when expressed in <it>E. coli </it>showed presence of cross-reaction as well as variant specific antibodies in malaria infected patient sera.</p> <p>Conclusion</p> <p>The present study demonstrates the existence of allele specific antibodies in <it>P. falciparum</it>-infected patient sera, however their role in protection requires further investigation. These results thereby, suggest the importance of a multi-allelic PfMSP-1₁₉based vaccine for an effective malaria control.</p>